Hepatitis B treatment approval, prescription companion apps and inequalities in NCD care.
Hepatitis B
FDA approves first antisense treatment for chronic hepatitis B
The FDA approved Hibsago (bepirovirsen) alongside existing antiviral therapy for eligible adults with suppressed chronic hepatitis B who do not have cirrhosis. In clinical trials, 19% of treated patients maintained viral control 24 weeks after stopping all hepatitis B therapy; the medicine carries a boxed warning for serious liver reactions and low platelet counts.
Why it matters: Introduces a new treatment mechanism that may allow selected patients to discontinue long-term antiviral therapy under careful clinical monitoring.
FDA clarifies regulation of companion apps for prescription medicines
New FDA guidance explains when pharmaceutical companies must submit companion-app content for regulatory review and reference an app in prescribing information. Apps essential to safe medicine use or providing meaningful clinical benefit may require label inclusion, while most patient-facing app content will be treated as promotional material.
Why it matters: Provides important direction for pharmaceutical companies developing adherence tools, connected devices and other digital services around prescription brands.
WHO maps inequalities affecting noncommunicable-disease care
WHO released its first global assessment systematically examining inequalities across cancer, cardiovascular disease, chronic respiratory disease and diabetes. It identifies disparities in risk exposure, screening, diagnosis and treatment associated with factors including income, education, gender, disability and rural residence.
Why it matters: Gives policymakers and healthcare organisations evidence for targeting NCD programmes toward populations experiencing the greatest barriers to prevention and care.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.